Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company reported sales of $627.7 ...
Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by ...
Neurocrine Biosciences exceeded earnings expectations ... in its pipeline and strategic collaborations with firms like Takeda. Ingrezza's success and ongoing innovation in R&D are fundamental ...
Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator Instructions) Please note today's call will be recorded and I will be ...
Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.
Neurocrine's Phase 3 pipeline is also set to ... we have that came out of the Phase 2 program and quite frankly, so was Takeda. As we've seen from Takeda over the past several years, they've ...
Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The business has a 50-day moving average of $138.41 and a 200-day moving average of $131.64.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results